George Willis ‘21 pitched Dexcom (NASDAQ: DXCM) on April 19th, 2021. Dexcom is a developer, manufacturer, and distributor of diabetes management systems which allow for continuous glucose monitoring. Diabetes is the 7th leading cause of death in the US and impacts as many as 1 in 3 Americans. Dexcom holds 25% of the addressable market in assisting people living with diabetes in monitoring their glucose levels more effectively and efficiently. The main drivers of George’s pitch were the strong growth opportunities within the addressable market space, the release of new products by Dexcom, and a strong management team where executive compensation is tied to the company achieving its goals. The class voted to buy 75 shares of DXCM at market price and sell 75 shares of SPY at market price on April 19th.